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Flu fears escalate
Fears of avian influenza crossing
the species barrier and creating a
new pandemic of human influenza
have cropped up time and again
this year, especially when new
outbreaks of bird flu were
observed in places far away from
its original breeding grounds in
Southeast Asia (Curr. Biol. 15,
R740). The most recent outbreaks
in Turkey, Romania and Greece,
coinciding with the news that US
researchers have not only
published the genome sequence
of the virus that caused the
deadly ‘Spanish Flu’ in 1918, but
also recreated this virus in the lab
and experimented with it, have
added to these worries.
The outbreak in Turkey at the
beginning of October has led the
European Union to ban all imports
of live birds from this country and
restrictions are under way in
Greece. Together with cases in
Romania, this might create the
impression that avian influenza is
closing in on Europe. On the other
hand, suspected cases reported
from Finland in the summer have
since then tested negative.
Moreover, people in Europe do
not tend to live as close to their
birds as those in Southeast Asia,
so, even if bird flu spread to
Europe, it would still be more
likely to cross the species barrier
to humans in Asia than anywhere
else. So, while the virus may be
hitching a ride on migrating birds,
the risks remain essentially
unchanged, and they are more
easily controlled in Europe than in
the poorer countries of Asia.
In contrast, the news that live
copies of the virus that caused the
‘Spanish flu’ pandemic in 1918 are
being cultivated in US
laboratories, together with the
publication of the entire genome
of the pathogen has added a new
dimension to the discussion. This
work delivers a prime example of
the so-called ‘dual-use’ research,
The new strain of bird flu first identified in southern Asia has now reached
Europe, raising local fears about a jump to humans as researchers have
controversially reconstructed the deadly Spanish flu virus as a means to
determine the factors contributing to its virulence. Michael Gross
reports.
Under threat: Europe’s poultry industry is facing a challenge from the virulent strain of bird flu first identified in southern Asia amidst
growing worries that it may transfer to humans. (Photo: EMPICS.)
which combines considerable
benefits with a significant risk that
the results may be misused for the
development of bioweapons. Only
recently, research organisations
have started to develop measures
to minimise such risks.
The foundation of this
controversial work is an
inconspicuous ‘letter’ in Nature,
where Jeffery Taubenberger and
his coworkers at the Armed
Forces Institute of Pathology at
Rockville, Maryland report the
sequences of the last three genes
of the virus, thus completing its
genome. As a prerequisite for its
publication, the researchers had
to make the sequence publicly
available in a database. Using this
sequence, the group of Terrence
M. Tumpey at the Center for
Disease Control and Prevention in
Atlanta, Georgia recreated the
virus and used it to infect
laboratory mice and study its
effects in comparison to modern
flu viruses. This work was
published in Science on October
7th, one day after the sequence
paper appeared in Nature.
The editors-in-chief of both
journals have underlined their
belief that the benefits
outweighed any risks.
Nevertheless, the reaction in the
general media contained more
than just an undertone of fear, as
the tens of millions who
succumbed to this virus in
1918/19 were evoked. Critics cited
in the media mainly expressed
fears over two aspects, firstly the
risk of the recreated virus
escaping from the lab (which is
only a level 3 biosecurity lab,
while the highest security level
would be 4), and secondly the risk
of somebody rebuilding their own
copy of the virus based on the
published sequence.
While not denying these risks,
proponents of the publications
play them down. They point out,
for example, that today’s
population is immunologically less
naive and better protected by
medical services and vaccination
programs than that of 1918. When
the Spanish flu first struck,
science knew nothing about the
virus, and flu vaccines did not
exist. Hence, an inadvertant or
even a malicious release of the
same virus might today have less
catastrophic effects than it had
back then.
The big benefit, which, in the
eyes of the researchers,
outweighs the risks, is that they
are hoping to understand how the
1918 virus crossed the species
barrier and what made it so
deadly. With this knowledge, they
are hoping to be able to avert any
future pandemics that would
otherwise be likely to result from
new variants crossing over into
the human population. In other
words, they have recruited the
devil they know against the even
more fearsome devils that are
lurking in our uncertain future.
There would have been a
significant risk in both
possibilities, in doing or not doing
this research. Let us hope that the
researchers have correctly
identified the smaller and more
manageable risk.
Meanwhile the media have
pounced on the potential risks of
the new strain of virulent bird flu
passing to humans whether or not
it comes from Europe or southern
Asia. British government officials
have also been warning that a
human pandemic of a new flu
virus strain is not a question of “if”
but “when” with high-profile
media response. 
Britain’s chief medical advisor,
Liam Donaldson, announced in
the wake of the Turkish and
Romanian test results that a
pandemic could lead to 50,000
excess deaths in Britain.
Efforts are under way to
stockpile doses of anti-flu drugs
in many countries and also to
develop potential vaccines. But
pharmaceutical companies and
researchers are under
unprecedented pressure from this
level of demand. The key
uncertainty is just how virulent
any new hybrid virus might be. A
major hope now is that detailed
knowledge of the Spanish flu virus
will help inform in one way or
another the likely impact of any
new flu threat posed by the new
bird flu strain.
Michael Gross is a science writer based
at Oxford. He can be contacted via his
web page at
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Animal rights activists in Britain
appear to have broadened their
activities to target contractors and
other suppliers in the face of
restrictions on their direct action
outside labs.
Building and decorating firms
have been sent threatening letters
believed to be from animal rights
activists warning them not to
work for Oxford University which
is constructing a major new
biomedical facility at its science
campus in the heart of the city.
The local Thames Valley police
said it knew of 18 anonymous
letters that tell contractors that
they will be targeted by the
militant Animal Liberation Front
(AFL) group if they undertake work
for the university.
Detectives believe it is likely
other people may have been
targeted, but chose not to report
the letter to the police. A police
spokesman said: “It is believed the
letters are part of a campaign by
animal rights extremists who are
trying to prevent work by Oxford
University to build new
laboratories.
“Although everyone is entitled to
an opinion about this very emotive
issue, it is just not acceptable to
act in a way which intimidates
other people and threatens their
livelihood.”
An Oxford University
spokesman said: “The university
remains firmly committed to the
completion of its new biomedical
research facility, which has been
designed to reflect the latest
understanding of best practice in
animal welfare.
“It is totally unacceptable that
companies engaged in entirely
lawful activities are being
threatened in this way. We would
urge anyone who receives such a
letter to contact the police
immediately.”
Animal rights
protests build
Opposition to animal experiments
in Britain appears to be extending
beyond the labs to other
businesses supplying them. Nigel
Williams reports.
